Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review

The STAR Study: A Real-World, International, Observational Study of the Safety and Tolerability of, and Adherence to, Serum-Free Subcutaneous Interferon β-1a in Patients With Relapsing Multiple Sclerosis

(2014) Raymond Hupperts et al.   CLINICAL THERAPEUTICS

Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies

(2014) Dean M. Wingerchuk et al.   MAYO CLINIC PROCEEDINGS

Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis

(2014) Niklas Bergvall et al.   JOURNAL OF MEDICAL ECONOMICS

Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel

(2014) J. Theodore Phillips et al.   Multiple Sclerosis and Related Disorders

Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study

(2013) Neetu Agashivala et al.   BMC Neurology

Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence

(2012) G Giovannoni et al.   Multiple Sclerosis Journal

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis

(2011) Rachel Halpern et al.   Patient Preference and Adherence

Factors that influence adherence with disease-modifying therapy in MS

(2009) Katherine Treadaway et al.   JOURNAL OF NEUROLOGY

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET